118 related articles for article (PubMed ID: 24432033)
1. Novel therapeutic modalities and drug delivery in pancreatic cancer - an ongoing search for improved efficacy.
Zhang Y; Satoh K; Li M
Drugs Context; 2012 Dec; 2012():212244. PubMed ID: 24432033
[TBL] [Abstract][Full Text] [Related]
2. Targeted drug delivery in pancreatic cancer.
Yu X; Zhang Y; Chen C; Yao Q; Li M
Biochim Biophys Acta; 2010 Jan; 1805(1):97-104. PubMed ID: 19853645
[TBL] [Abstract][Full Text] [Related]
3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
[TBL] [Abstract][Full Text] [Related]
5. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
[TBL] [Abstract][Full Text] [Related]
6. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
7. Targeted Dual Intervention-Oriented Drug-Encapsulated (DIODE) Nanoformulations for Improved Treatment of Pancreatic Cancer.
Madamsetty VS; Pal K; Dutta SK; Wang E; Mukhopadhyay D
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32397114
[TBL] [Abstract][Full Text] [Related]
8. A novel siRNA-gemcitabine construct as a potential therapeutic for treatment of pancreatic cancer.
Simonenko V; Lu X; Roesch E; Mutisya D; Shao C; Sun Q; Patterson-Orazem A; McNair M; Shanmuganathan A; Lu P; Evans DM
NAR Cancer; 2020 Sep; 2(3):zcaa016. PubMed ID: 34316688
[TBL] [Abstract][Full Text] [Related]
9. Target therapies in pancreatic carcinoma.
Silvestris N; Gnoni A; Brunetti AE; Vincenti L; Santini D; Tonini G; Merchionne F; Maiello E; Lorusso V; Nardulli P; Azzariti A; Reni M
Curr Med Chem; 2014; 21(8):948-65. PubMed ID: 23992319
[TBL] [Abstract][Full Text] [Related]
10. Advanced stage pancreatic cancer: novel therapeutic options.
Saif MW
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):487-98. PubMed ID: 24939470
[TBL] [Abstract][Full Text] [Related]
11. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib: the first biologic in the management of pancreatic cancer.
Saif MW
Expert Opin Pharmacother; 2008 Jun; 9(9):1595-607. PubMed ID: 18518788
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future.
Cohenuram M; Saif MW
JOP; 2007 Jan; 8(1):4-15. PubMed ID: 17228128
[TBL] [Abstract][Full Text] [Related]
14. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
[TBL] [Abstract][Full Text] [Related]
15. Nanotechnology: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(19):1-43. PubMed ID: 23074489
[TBL] [Abstract][Full Text] [Related]
16. Targeted Therapies for Pancreatic Cancer and Hurdles Ahead.
Aslan M; Shahbazi R; Ulubayram K; Ozpolat B
Anticancer Res; 2018 Dec; 38(12):6591-6606. PubMed ID: 30504367
[TBL] [Abstract][Full Text] [Related]
17. Combinational therapy: new hope for pancreatic cancer?
Shi S; Yao W; Xu J; Long J; Liu C; Yu X
Cancer Lett; 2012 Apr; 317(2):127-35. PubMed ID: 22138436
[TBL] [Abstract][Full Text] [Related]
18. Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside.
Yang F; Jin C; Jiang Y; Li J; Di Y; Ni Q; Fu D
Cancer Treat Rev; 2011 Dec; 37(8):633-42. PubMed ID: 21330062
[TBL] [Abstract][Full Text] [Related]
19. Current concepts and novel targets in advanced pancreatic cancer.
Michl P; Gress TM
Gut; 2013 Feb; 62(2):317-26. PubMed ID: 23112132
[TBL] [Abstract][Full Text] [Related]
20. Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review.
Bhosale RR; Gangadharappa HV; Hani U; Ali M Osmani R; Vaghela R; Kulkarni PK; Koganti VS
Curr Drug Targets; 2017; 18(11):1233-1249. PubMed ID: 27296312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
